Uncovering Potential: Fulcrum Therapeutics's Earnings Preview

Fulcrum Therapeutics FULC is set to give its latest quarterly earnings report on Thursday, 2025-05-01. Here's what investors need to know before the announcement.

Analysts estimate that Fulcrum Therapeutics will report an earnings per share (EPS) of $-0.26.

Fulcrum Therapeutics bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.

New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).

Overview of Past Earnings

The company's EPS missed by $0.02 in the last quarter, leading to a 10.27% drop in the share price on the following day.

Here's a look at Fulcrum Therapeutics's past performance and the resulting price change:

Tracking Fulcrum Therapeutics's Stock Performance

Shares of Fulcrum Therapeutics were trading at $3.65 as of April 29. Over the last 52-week period, shares are down 49.41%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release.

To track all earnings releases for Fulcrum Therapeutics visit their earnings calendar on our site.

This article was generated by Benzinga's automated content engine and reviewed by an editor.